| This week's sponsor is FierceBiotech’s Drug Development Forum. | | FierceBiotech’s Drug Development Forum – September 19-21, 2016 Join leading biotech professionals in the first-ever Drug Development Forum in Boston. Discover the latest trends, challenges, and innovations in the biotech industry. Sign up by July 29, 2016 and save $200 on registration.
Register now |
Top Stories Tuesday, July 5, 2016 Less than a week after stumping up cash for a one-drug-wonder biotech (and an option to buy it out), Japan’s Takeda has struck another biotech deal, this time with Belgium-based TiGenix. Tuesday, July 5, 2016 Insys Therapeutics has gained an FDA approval for the latest iteration of synthetic THC--a liquid formulation of dronabinol, a pharmaceutical version of tetrahydrocannabinol (THC). Tuesday, July 5, 2016 China upstart CStone Pharma has raised a major $150 million in a Series A funding drive as it looks to boost its research in immuno-oncology. Tuesday, July 5, 2016 This spring, Aprecia Pharmaceuticals launched the first 3-D printed pharmaceutical product to be approved by the FDA. It’s now secured $30 million in debt to aid that launch and bring forward more 3-D printed fast-melt formulations. Tuesday, July 5, 2016 Johnson & Johnson has exercised its option to license FR104 from OSE Immunotherapeutics. The agreement, which follows shortly after the conclusion of a Phase I trial of FR104, sees J&J commit to pay up to €155 million for the global rights to the CD28 antagonist in autoimmune diseases and transplantations. | | | Israeli biotech Can-Fite BioPharma’s subsidiary, OphthaliX, missed its primary endpoint in top-line results from its Phase II clinical trial of CF101 in glaucoma. Release. Cambridge, MA-based Warp Drive Bio has appointed biotech veteran and former GlycoMimetics CEO Rachel King to its board of directors. Statement. Ireland-based Prothena Corporation has posted new data from the Phase I/II dose-escalation and expansion study of NEOD001, its lead program as a potential disease-modifying therapy for AL amyloidosis. Release. The FDA has accepted an NDA from Chapel Hill, NC-based Cempra for Solithera (solithromycin) as a treatment for community-acquired bacterial pneumonia. Statement. Biogen and AbbVie’s new, once-monthly multiple sclerosis jab Zinbryta (daclizumab) has been approved in Europe. Release. | |
|
Resources Sponsored by: SDC Interested in intended use validation of SaaS-based EDC systems? Prefer to discuss rescue study strategies and considerations? How about understanding statistical power for non-statisticians? Vote for your favorite webinar topic to be presented by SDC at DIA on June 28, 2016, 12pm EDT. Cast Your Vote Here to receive your exclusive event invitation and a recording of the webinar after the event. Sponsored by: Covance Al Blunt, MD, Executive Medical Director, Oncology at Covance discusses how the lessons learned from the past decade of developing targeted therapies are relevant to the future development of cancer immunotherapy. Download today! Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. |
|
